VANCOUVER, BC, Dec. 15, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is proud to announce that its research site, Cedar Clinical Research (CCR), has been chosen as one of multiple sites for Beckley Psytech's cutting-edge Phase 2b clinical trial for Treatment Resistant Depression (TRD).
Read more at newswire.caCedar Clinical Research selected as clinical research site for Beckley Psytech's Phase 2b Study
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
